Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roth (link attached) is projecting almost as much in sales of Vascepa in Europe as they are in the U.S.
https://roth2.bluematrix.com/sellside/EmailDocViewer?mime=pdf&co=Roth2&id=shorta_are_retards@bluematrix.com&source=mail&encrypt=a40e4193-d1f7-4456-9f14-05b4c63220b9
I've been baking cookies for two days even though I know better. Will spread them out to all the friends and family over the next week. I'm lucky enough to take my Vascepa twice a day. I will try and spread the word as I am passing out cookies.
There are exceptions.
So they were all exercised options.
Options seem to be a fools game with AMRN. Long shares only has been the way to go. All that the large numbers of options have done is created manipulation all of us end up having to deal with.
Lots of new names posting on the board right now, where did they all come from? Cockroaches crawling out from under the woodwork.
Who are you talking to. This was known early today.
Oh come on, there were no whale's bailing. This was shorts shorting, pure and simple. If someone long bailed it was because they had no idea what they owned.
Yes, it does. I can't believe I am going to say this but keep an eye on the scripts. The increasing scripts are increasing revenue and increasing valuation. These same analyst will raise their price targets as Amarin raises guidance. Most of us have been here for the long term with this one and are not going to have one more bear raid take us out.
It starts with the news flow and the $8 price targets. Creating doubt. CNBC bringing up the patent trial as if there is actually any doubt that this will be settled or go to trial in Amarin's favor. No one really thinks that Amarin is going to lose patent coverage. There is nothing in the documents at all that would lead anyone with reasonable knowledge to believe that. CNBC bring up fish oil, making it sound like this is nothing to write home about when the cardiologist are falling all over themselves because they have a safe effective drug to treat patients. And then there are the low ball estimates of sales. Jeffereies yesterday just said that their low ball scenario is for 500M in sales. Well Amarin has 500 M in sales right now. That is ridiculous. Seeds of doubt to try to get you to sell.
Then look at the trading this morning. At the detailed trades, 5 and 10 shares at the bid to try to get you to sell your shares, over and over. Shorts selling shares they do not have to try to get you to sell.
Volume is fairly low this morning. They are just walking the price down. Short interest is keeping the price down. It will only be temporary.
You do realize they are already at a 500M a year run rate.
He said that waiting has premium attached, so he plans on waiting. Basically he is talking buyout premium. If he waits to partner Europe, buyout for the whole company is still on the table.
You must not have been reading the board Friday evening.
Statin intollerant are covered under the label. Thank God they covered this so we can put it to bed.
Peak sales of Amarin's Vascepa being underappreciated, says Cantor Fitzgerald The FDA's approved patient population of Amarin's Vascepa is in-line with Street expectations, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. The agency on Friday approved the use of Vascepa as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels of 150 milligrams per deciliter or higher. Vascepa is the first FDA approved drug to reduce CV risk among patients with elevated triglyceride levels as an add-on to maximally tolerated statin therapy, Chen points out. The analyst thinks the peak sales potential of Vascepa is underappreciated. Upward earnings revisions to levels not reflected in consensus expectations should drive Amarin shares higher, contends Chen. The analyst affirms an Overweight rating on the stock with a $35 price target. Amarin in premarket trading is up 10% to $26.45.
Read more at:
https://thefly.com/landingPageNews.php?id=3007114
I was just getting ready to say something similar. Start a patient that has had prior statin trouble on Vascepa and then at the next check up try and add in a low dose statin to see if they can tolerate it in combination.
Tasty, there is no age limit on the label so you do not start with the over 50 population.
"You need to have diabetes or heart disease and then two more risk factors. I don't believe stress & family history qualify. If your triglycerides are 150 and above, you qualify for on-label. "
That is not true. Look at the label.
VASCEPA is an ethyl ester of eicosapentaenoic acid (EPA) indicated:
• as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable
angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
o established cardiovascular disease or
o diabetes mellitus and 2 or more additional risk factors
for cardiovascular disease. (1)
• as an adjunct to diet to reduce TG levels in adult patients with severe
(≥ 500 mg/dL) hypertriglyceridemia. (1)
Once the new label comes out there will be no equal.
Any upfront payment type deal with a partnership (Europe partnership as an example) could impact current year but majority of M&A would all be booked in the year that buyout is finalized.
CDEC is not an Adcom. It does not have to do with approval. It has to do with cost analysis and reimbursement.
Updated short interest
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
11/29/2019 45,868,031 13,036,251 3.518499
11/15/2019 48,386,316 16,603,924 2.914149
10/31/2019 55,636,054 4,495,460 12.376054
10/15/2019 50,439,425 5,934,641 8.499154
09/30/2019 51,736,586 4,794,620 10.79055
09/13/2019 50,869,825 6,997,767 7.269437
Any future generics would need to also tackle the Reduce-it patents. That would be impossible.
Same exact type of case as the TEVA case and TEVA settled.
It looks to me like it is about biologics.
Instead of publicizing it, why don't you send the links to Amarin Corp and the FDA so they can get it pulled off the site.
Make sure to hold out money for your tax liability.
This is how Benzinga is promoting this, this morning. Jackasses..
Amarin Corp, Inc. (NASDAQ:AMRN) stock rose 1.6% to $21.61. The market cap stands at $5.8 billion. The most recent rating by Oppenheimer, on November 20, is at Underperform, with a price target of $7.00.
yes I know, should is in quotes, just pointing out what should happen.
Now that EMA accepted application, analyst "should" adjust price targets now that cash flow should begin in EMA at beginning of 2021.
He said currently at the end of 2018/ beginning of 2019. We are a long way from there.
There is an unnecessary message board fear regarding settlement. Anyone filing after approval would need to deal not only with the current orange book patents but also the Reduce-it patents that will be added.
Is this your article.? The post you are responding to does not even mention the article. Why are you promoting it?
CADTH is not the same as Health Canada. I am not sure how many times this can be posted.
HLS has said some time in December.
Is this the trial where they gave the drug with a low fat breakfast?
report back from Jefferies call with Patent Lawyer
From dough
@semodough on twitter
$AMRN Key Takeaways from Call w/ Patent Lawyer + Preview of Upcoming Competitor Data-came away (+), with many of generic claims already abandoned or invalidated by court&view of settlement as probable or a high ~85% likelihood AMRN could win outright,potentially pushing it $25-30
expert $AMRN would likely win case outright (high probability, in his view) as many of generics' claims have been weakened Our DCF suggests stock is worth $30 on peak sales of $3-4B, every $1B higher peak flows to bottom line is worth $5/sh upside.
JEFF $AMRN Monday (11/25) at 1pm ET, we will be hosting a conference call with patent lawyer Jacob Sherkow to discuss the ongoing Vascepa patent litigation with Dr. Reddy and Hikma. We will discuss the recently published summary judgment and scenarios for upcoming litigation
9:38 PM · Nov 28, 2019·Twitter for iPhone
Sam is the link.
Thanks Sam, great numbers.
The larger the base is the harder it should be to see these types of numbers but look at that pill count increase. Fantastic.